Evidence map›Paper›PMID 42639779›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026

Effect of Jinlong capsule on the survival of patients with hepatocellular carcinoma: a propensity score matching study.

Shi Ke, Zhang Yi, Sun Lina, Wang Xianbo, Feng Ying

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shi KeCenter of integrative medicine, Beijing Ditan Hospital, Capital Medical University, Beijing10015, China.
Zhang YiCenter of integrative medicine, Beijing Ditan Hospital, Capital Medical University, Beijing10015, China.
Sun LinaCenter of integrative medicine, Beijing Ditan Hospital, Capital Medical University, Beijing10015, China.
Wang XianboCenter of integrative medicine, Beijing Ditan Hospital, Capital Medical University, Beijing10015, China.
Feng YingCenter of integrative medicine, Beijing Ditan Hospital, Capital Medical University, Beijing10015, China.

Funding

a Study on the Effect of Fuzheng Jidu Xiaoji Prescription on Regulating Pyruvate Kinase M2 Lactate Modification to Enhance the Efficacy of Chimeric Cntigen Receptor T-cell Cells Based on Hepatocellular Carcinoma Organoid Symbiosis System 82474426Beijing High-level Innovation and Entrepreneurship Talent Support Programein-young Backbone Talent Projects: Evaluation of the Huoxue Jianpi Formula for Preventing Carcinogenesis in Hepatitis B-related Cirrhosis and the Establishment of an Early Warning System G202532309Beijing Municipal Natural Science Foundation: a Study on the Mechanism of Fuzheng Jiedu Xiaoji Formula Inhibiting Signal Transducer and Activator of Transcription 3 Pathway to Improve the Efficacy of Dual-target Chimeric Cntigen Receptor T-cell Based on Hepatocellular Carcinoma Organoids 7232272Capital's Funds for Health Mprovement and Research: a Study on the Therapeutic Effect of Shugan Jianpi Huoxue Prescription on High Risk Population of Liver Cancer with Liver Cirrhosis in Compensatory Period and the Key Technology of Early Warning of Liver Cancer 2024-1-2173National Natural Science Foundation of China: a Study on the Jiedu Liangxue Jianpi Decoction Inhibits Acute Liver Failure by Targeting Neutrophil Extracellular Traps Formation Induced by Wilms' Tumor 1-associating Protein/N6-methyladenosine-ras Homolog Family Member A/Macrophage-1 Antigen Axis 82474419
6 · The paper itself

Abstract

objectiveTo evaluate the impact of Jinlong capsule on the overall survival (OS) rates of patients with hepatocellular carcinoma (HCC) at various stages of the disease.

methodsA total of 799 patients diagnosed with HCC between January 2016 and December 2019 were enrolled. The three-year OS rate of the Jinlong group (

resultsThe Cox regression model revealed that Jinlong treatment was independently associated with an improved three-year OS. The Jinlong group had a significantly higher OS rate than the control group, with an adjusted hazard ratio of 0.48 (95% confidence interval: 0.38-0.60;

conclusionsJinlong treatment significantly improved the three-year survival rate of patients with HCC. These findings provide a foundation for further studies into the effectiveness of Jinlong capsule in the treatment of HCC.

Indexed as

Carcinoma, HepatocellularDrugs, Chinese HerbalLiver NeoplasmsAdultAgedCapsulesFemaleHumansMaleMiddle AgedPropensity ScoreCapsulesDrugs, Chinese HerbalChinese patent medicinecohort studiesJinlong capsuleliver cancerpropensity score matching, prognosis

Identifiers

PMID42639779
PMCPMC13494880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.